MENTIS Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • MENTIS's estimated annual revenue is currently $9.5M per year.(i)
  • MENTIS's estimated revenue per employee is $130,500

Employee Data

  • MENTIS has 73 Employees.(i)

MENTIS's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$22.6M142-18%N/AN/A
#2
$41.3M25944%N/AN/A
#3
$808.8M39849%N/AN/A
#4
$1320M19018%$445MN/A
#5
$513.8M247811%$215MN/A
#6
$16.7M1154%N/AN/A
#7
$469.4M22648%$298.8MN/A
#8
$84.3M46533%N/AN/A
#9
$19.4M127-2%$46.6MN/A
#10
$81.2M44825%N/AN/A
Add Company

What Is MENTIS?

keywords:N/A

N/A

Total Funding

73

Number of Employees

$9.5M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

MENTIS News

2022-04-13 - Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Health and Cancers

Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology,...

2022-04-13 - BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, New Drugs for Cancers, Glaucoma, and Autism, and Diagnostics.

BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue...

2022-04-06 - Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism

Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.5M73-35%N/A
#2
$13.5M73-30%N/A
#3
$5.7M73-17%$629.5M
#4
$9.5M73-35%N/A
#5
$16.4M73-15%N/A